Actively Recruiting
Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial
Led by Beni-Suef University · Updated on 2026-05-20
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the protective effects of a combination of diosmin and hesperidin on kidney damage caused by platinum-based chemotherapy in cancer patients. This prospective randomized controlled study aims to understand whether this combination can reduce nephrotoxicity associated with platinum compounds used in cancer treatment. The study involves about 100 cancer patients between 18 and 75 years old who are receiving platinum compound chemotherapy. Participants are divided into two groups: one group receives standard platinum compound chemotherapy alone, while the other group receives the same chemotherapy plus an oral dose of 450 mg diosmin and 50 mg hesperidin twice daily. The study is conducted from February 2025 to September 2025, with follow-up continuing for 6 months after treatment to assess kidney function. During the study, researchers will measure serum creatinine and blood urea levels six months after treatment to evaluate kidney health. They will also monitor hemoglobin levels as a secondary outcome. Participants will be closely observed for any side effects and adherence to the treatment protocol. The study is sponsored by Beni-Suef University and aims to provide insights into managing chemotherapy-induced kidney damage in cancer patients.
CONDITIONS
Brief Title
Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 75 years
- Histologically or cytologically confirmed cancer
- Receiving platinum compound chemotherapy
You will not qualify if you...
- History of allergic reactions to study drugs
- Pregnant women
- Life expectancy less than 6 months
- Unable or unwilling to follow research protocols
- Impaired kidney function (creatinine clearance less than 50 mL/min)
- Preexisting hearing loss
- Taking nephrotoxic drugs
- History of allergic reactions to platinum-containing compounds
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Duration - Up to 6 months
Participants receive standard platinum compound chemotherapy; those in the test group also take diosmin and hesperidin orally twice daily.
Visits occur according to chemotherapy cycles, with additional visits for study assessments
Trial Site Locations
Total: 1 location
1
Faculty of Medicine
Banī Suwayf, Egypt, 0000
Actively Recruiting
Research Team
M
marwa mohsen, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here